SCHEMBL18220154

SCHEMBL18220154

COCCNS(=O)(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(NCCN4CCOCC4)ccc3c2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.39
MMP8 P22894 1/20 0.39
MMP12 P39900 1/20 0.39
MMP13 P45452 1/20 0.39
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 3/20 0.37
GAA P10253 3/20 0.37
HPGD P15428 2/20 0.37
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
SCN9A Q15858 1/20 0.36
CNR2 P34972 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
SYK P43405 3/20 0.35
GCK P35557 1/20 0.35
KMT2A Q03164 2/20 0.35
TLR9 Q9NR96 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23134336 0.91 SCN9A (0.36) MMP12ALDH1A1KDM4EGAAHPGD
SCHEMBL25609517 0.90 ALDH1A1 (0.39) MMP2MMP8MMP12MMP13ALDH1A1
SCHEMBL18220275 0.87 ALDH1A1 (0.37) MMP2MMP8MMP12MMP13ALDH1A1
SCHEMBL18220167 0.87 ALDH1A1 (0.48) ALDH1A1KDM4EGAAHPGDCACNA1B
SCHEMBL18221615 0.86 SCN9A (0.37) MMP2MMP8MMP12MMP13ALDH1A1
SCHEMBL18219860 0.86 APP (0.44) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL18220165 0.85 APP (0.48) ALDH1A1KDM4EGAAHPGDSYK
SCHEMBL18220180 0.85 WNT3A (0.38) MMP2MMP8MMP12MMP13ALDH1A1
SCHEMBL18220135 0.85 ALDH1A1 (0.49) MMP2MMP8MMP12MMP13ALDH1A1
SCHEMBL18220186 0.85 CA1 (0.37) MMP2MMP8MMP12MMP13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10934264-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-03-02 US disclosed
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-04-23 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MMP2 2911/4885MMP8 3575/4885MMP12 3127/4885
US-20200123118-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MMP2 2911/4885MMP8 3575/4885MMP12 3127/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MMP2 2911/4885MMP8 3575/4885MMP12 3127/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA MMP2 3036/4885MMP8 3618/4885MMP12 3170/4885
US-10934264-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MMP2 2911/4885MMP8 3575/4885MMP12 3127/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA MMP2 3036/4885MMP8 3618/4885MMP12 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.